Pharmaceutical Supply Chain: Essential Tax and Financial Strategies for 2025

The pharmaceutical supply chain represents one of the most intricate commercial ecosystems in modern business, spanning raw material suppliers, manufacturers, wholesalers, distributors, pharmacies, and healthcare providers. With the industry facing unprecedented challenges—from global supply disruptions to evolving regulations—understanding the tax and financial implications of supply chain decisions has become critical for pharmaceutical companies, investors, and finance professionals.

Current Industry Landscape: By the Numbers

The pharmaceutical logistics market continues its robust expansion, with the global pharmaceutical logistics market size valued at USD 111.45 million in 2024 and predicted to reach USD 181.07 million by 2033. This growth reflects the increasing complexity of drug distribution networks and the rising demand for specialized logistics solutions.

Meanwhile, industry leaders are investing heavily in technology to build resilience. More than 85% of biopharma executives surveyed say they are investing in data, AI and digital tools in 2025 to build supply chain resiliency, and 90% of these executives said they are investing in smart manufacturing to increase supply chain efficiency.

The sector also faces ongoing challenges, with the global pharmaceutical supply chain management market size expected to reach $3.63 billion by 2028 at a rate of 8.7%, driven by the need for greater visibility and control across increasingly complex global networks.

Critical Tax Considerations for Pharmaceutical Supply Chains

Transfer Pricing and Intercompany Transactions

Pharmaceutical companies operating through international subsidiaries face complex transfer pricing requirements. The pricing of goods, services, and intellectual property between related entities must comply with IRS Section 482 and OECD guidelines to avoid significant tax exposures, including penalties and interest.

Key compliance areas include:

• Documentation supporting arm’s-length pricing for active pharmaceutical ingredients (APIs), licensing fees, and R&D services
• Regular review of transfer pricing policies when supply chain flows change, such as relocating manufacturing operations
• Audit readiness as local tax authorities increasingly scrutinize pharmaceutical intercompany transactions

Inventory Valuation and Cost of Goods Sold Recognition

The timing and valuation of inventory purchases from suppliers can substantially impact taxable income. Under U.S. tax law, pharmaceutical companies may use specific identification, FIFO, or weighted average methods, but consistency and IRS conformity rules remain essential.

Common challenges include:

• Proper matching of costs and revenues to accurately state taxable income
• Managing large purchases made in anticipation of shortages without distorting reported profits
• Handling inventory obsolescence due to product expiration, regulatory changes, or market shifts

Customs Duties and Import Considerations

The pharmaceutical industry has historically benefited from low or zero tariffs under international trade agreements. However, recent policy changes have introduced new complexities. In 2024, the U.S. imported $168 billion worth of finished and unfinished pharmaceutical products, making customs compliance increasingly important.

Current developments affecting the industry include:

• Proposed tariffs on pharmaceutical imports, with total tariff measures potentially increasing from $0.5 billion a year to nearly $63 billion a year for the Pharmaceutical, Life Science, and Medical Device industry
• The need for accurate classification of imports under the Harmonized Tariff Schedule
• Strategic opportunities through Free Trade Zone designation and duty drawback programs

Tax planning strategies include:

• Utilizing available duty drawback programs for qualifying transactions
• Establishing Free Trade Zone operations for packaging and distribution facilities
• Structuring product transformation activities to optimize tariff classifications

State and Local Tax Complexities

Decentralized warehousing and distribution operations create nexus obligations across multiple states, triggering various state income, franchise, and sales tax requirements.

Key issues include:

• Varying apportionment formulas across different states
• Proper management of reseller certificates and exemption compliance
• Economic nexus considerations arising from drop shipment arrangements and third-party logistics relationships

Financial Reporting Best Practices

Revenue Recognition Under ASC 606

Revenue from pharmaceutical sales must account for the industry’s unique characteristics, including chargebacks, rebates (including Medicaid programs), returns, and complex wholesaler stocking arrangements.

Common reporting challenges:

• Accurate estimation of expected returns based on historical data and market conditions
• Proper classification of incentives and rebates as deductions from gross revenue rather than cost of goods sold
• Managing revenue recognition for specialty pharmacy and direct-to-patient programs

Managing Inventory Risk and Obsolescence

The pharmaceutical industry faces significant write-off risks due to regulatory shelf life requirements, product recalls, and rapid market changes. GAAP requires regular impairment testing to ensure accurate financial reporting.

Financial impact considerations:

• Margin compression from necessary write-downs
• Potential earnings restatements if impairment recognition is delayed
• Impact on cash flow and working capital management

Capital Investment vs. Expense Treatment

Pharmaceutical distribution and repackaging operations often require substantial facility investments. Proper determination of capitalization versus expense treatment under ASC 360 and IRC Section 263(a) can materially impact both EBITDA and taxable income.

Strategic Supply Chain Transformation Opportunities

Nearshoring and Domestic Manufacturing Incentives

Post-pandemic policies have created incentives for U.S.-based pharmaceutical production. Mexico has seen significant foreign direct investment through nearshoring, including $36 billion in 2023, with announced commitments in the first five months of 2024 of an additional $39 billion.

Available incentives may include:

• Federal and state tax credits, including New Markets and R&D credits
• Accelerated depreciation benefits through bonus depreciation or Section 179
• Negotiated PILOT agreements and tax holidays for new facility construction

Third-Party Logistics and Outsourcing Considerations

While outsourcing can reduce operational complexity, it introduces additional tax compliance requirements and financial reporting considerations, particularly around contract fulfillment models and revenue recognition.

Technology Investment and Digital Transformation

The industry’s digital transformation continues accelerating, with spending on AI expected to reach $3 billion by 2025 as companies invest in technology that may reduce the time and costs required to bring a new drug to market. These technology investments often qualify for various tax incentives while improving supply chain efficiency and compliance capabilities.

Expert Financial and Tax Advisory Services from HBK

Effectively managing the financial and tax aspects of the pharmaceutical supply chain requires more than compliance—it demands insight into operational realities, regulatory pressures, and strategic decision-making. Joshua Zarlenga, CPA and Principal at HBK CPAs & Consultants, works closely with U.S.-based pharmaceutical companies, wholesalers, and healthcare providers to ensure that their supply chain operations align with sound financial management and tax efficiency.

HBK’s Supply Chain and Tax Advisory Services Include:

Inventory and Revenue Recognition Guidance: Supporting accurate treatment of drug inventory, chargebacks, rebates, and returns under GAAP and ASC 606 to ensure financial transparency and audit readiness.

Cost of Goods Sold and Overhead Allocation: Helping businesses properly allocate direct and indirect costs to inventory, optimize gross margins, and manage cost flows across warehousing, packaging, and distribution.

Multi-State Tax Exposure and Nexus Review: Evaluating state and local tax risks created by warehousing, delivery routes, and distribution contracts, and developing strategies to remain compliant while minimizing exposure.

Customs Classification and Indirect Tax Optimization: Assisting U.S.-based importers with tariff classification, customs valuation, and duty minimization strategies, including the use of Free Trade Zones or duty drawback programs.

Facility Investment and Capitalization Planning: Advising on leasehold improvements, warehouse buildouts, and packaging equipment investments, ensuring appropriate capitalization, depreciation, and expensing strategies under Section 263(a) and bonus depreciation rules.

Tax Credit Identification and Application: Helping clients access R&D credits, domestic manufacturing incentives, and other state or federal programs applicable to pharmaceutical operations.

Whether you’re expanding a packaging facility, realigning warehousing operations, or navigating complex rebate and returns accounting, Joshua brings practical, actionable advice grounded in industry knowledge and financial integrity. HBK’s team delivers customized solutions to support both compliance and performance in an increasingly regulated and competitive healthcare market.

Conclusion: Positioning for Success in a Complex Environment

The pharmaceutical supply chain’s financial and tax implications extend far beyond operational logistics. From intercompany pricing strategies to inventory valuation, from customs optimization to revenue recognition, supply chain design decisions significantly affect tax liabilities, cash flow, and investor confidence.

As the industry evolves amid global pressures, regulatory changes, and emerging technologies, pharmaceutical companies must align their tax and finance strategies with supply chain operations. This alignment ensures compliance, mitigates risks, and unlocks long-term value in an increasingly competitive and regulated healthcare marketplace.

Success requires expertise that bridges operational knowledge with financial acumen—understanding not just how pharmaceutical supply chains work, but how they can work most effectively within the complex web of tax and financial requirements that govern modern pharmaceutical commerce.